written by reader Uveitis Drug Bonanza?

By xiexgp@gmail.com, November 20, 2014

With a sense of urgency I received this pitch (in a nutshell)

Institutions and insiders – including the FDA’s former Chief Counsel – have snapped up 83% of available shares of the amazing company I’ve been telling you about.

And for good reason. This tiny $4 company has developed a breakthrough drug to treat a devastating disease that blinds one American every 17 minutes.

Right now, this company’s sales are a mere $28 million.

But its new breakthrough could easily send sales soaring as high as $1.5 billion, creating a sales surge of over 5,695%.

And the story gets even more compelling. Because this drug has been granted ”Orphan Status” by the FDA, there’s a done-deal monopoly once approved that puts it on the ”bullet train” to profits.

But time is of the essence. My research signals Phase trial data could be announced any day now.

When that happens, this $4 stock could go absolutely vertical.

Based on standard valuation methods, a target price of $143 is enough to turn $1,000 into $35,000… or $10,000 into $350,000.

That’s why I’m opening up limited membership to the Biotech Insider Alert at a rate that saves you over $3,000 to keep in your pocket to give you a jump start on this $4 stock – or use any way you wish.

Sounds like a Gumshoe lead in. The letter is asking $1950/yr. Any quick ideas?
Sounds like a

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.